A citation-based method for searching scientific literature

Isabel Belinchón Romero, Esteban Dauden, Carlos Ferrándiz Foraster, Álvaro González-Cantero, Jose Manuel Carrascosa Carrillo. J Dermatolog Treat 2022
Times Cited: 3







List of co-cited articles
144 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity




How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review.
Phyllis I Spuls, Lidian L A Lecluse, Marie-Louise N F Poulsen, Jan D Bos, Robert S Stern, Tamar Nijsten. J Invest Dermatol 2010
157
100


Use of ustekinumab after other biological therapies in moderate-severe psoriasis: Real long-term data.
Manuel David Gil-Sierra, Esmeralda Ríos-Sánchez, María Del Pilar Briceño-Casado. Farm Hosp 2020
2
100

Analysis of body regions and components of PASI scores during adalimumab or methotrexate treatment for patients with moderate-to-severe psoriasis.
Alexander A Navarini, Yves Poulin, Alan Menter, Yihua Gu, Henrique D Teixeira. J Drugs Dermatol 2014
24
66

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
Kenneth B Gordon, Andrew Blauvelt, Kim A Papp, Richard G Langley, Thomas Luger, Mamitaro Ohtsuki, Kristian Reich, David Amato, Susan G Ball, Daniel K Braun,[...]. N Engl J Med 2016
486
66

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Christopher E M Griffiths, Kristian Reich, Mark Lebwohl, Peter van de Kerkhof, Carle Paul, Alan Menter, Gregory S Cameron, Janelle Erickson, Lu Zhang, Roberta J Secrest,[...]. Lancet 2015
563
66


Randomized clinical trials for psoriasis 1977-2000: the EDEN survey.
Luigi Naldi, Ake Svensson, Thomas Diepgen, Peter Elsner, Jean-Jacques Grob, Pieter-Jan Coenraads, Jan Nico Bouwes Bavinck, Hywel Williams. J Invest Dermatol 2003
95
66


Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.
A B Kimball, K B Gordon, S Fakharzadeh, N Yeilding, P O Szapary, B Schenkel, C Guzzo, S Li, K A Papp. Br J Dermatol 2012
91
66

Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis.
Boni Elewski, Alan Menter, Jeffrey Crowley, Stephen Tyring, Yang Zhao, Simon Lowry, Stephen Rozzo, Alan M Mendelsohn, Jeffrey Parno, Kenneth Gordon. J Dermatolog Treat 2020
8
66

Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS).
Xuejun Zhu, Min Zheng, Michael Song, Yaung-Kaung Shen, Daphne Chan, Philippe O Szapary, Baoxi Wang. J Drugs Dermatol 2013
60
66

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.
Kristian Reich, Melinda Gooderham, Diamant Thaçi, Jeffrey J Crowley, Caitriona Ryan, James G Krueger, Tsen-Fang Tsai, Mary Flack, Yihua Gu, David A Williams,[...]. Lancet 2019
121
66

Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies.
Gil Yosipovitch, Adam Reich, Martin Steinhoff, Anke Beselin, Toby Kent, Martin Dossenbach, Lovisa Berggren, Carsten Henneges, Thomas Luger. Dermatol Ther (Heidelb) 2018
9
66

Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3).
Andrew Blauvelt, Melinda Gooderham, Lars Iversen, Susan Ball, Lu Zhang, Noah O Agada, Kristian Reich. J Am Acad Dermatol 2017
79
66


Biosimilar and interchangeable: Inseparable scientific concepts?
Fernando de Mora, Alejandro Balsa, María Cornide-Santos, Jose-Manuel Carrascosa, Sara Marsal, Javier P Gisbert, Miguel-Angel Abad, Rafael F Duarte, Michael Wiechmann, Rafael Martínez. Br J Clin Pharmacol 2019
10
66



Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials.
R G Langley, A W Armstrong, M G Lebwohl, A Blauvelt, S Hsu, S Tyring, S Rastogi, R Pillai, R Israel. Br J Dermatol 2019
18
66


The self-administered psoriasis area and severity index is valid and reliable.
S R Feldman, A B Fleischer, D M Reboussin, S R Rapp, M L Exum, A R Clark, L Nurre. J Invest Dermatol 1996
210
66

Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions.
Alan Menter, Neil J Korman, Craig A Elmets, Steven R Feldman, Joel M Gelfand, Kenneth B Gordon, Alice Gottlieb, John Y M Koo, Mark Lebwohl, Craig L Leonardi,[...]. J Am Acad Dermatol 2011
323
66

Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).
Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, Luis Puig, Jamie Weisman, Yves Dutronc, Lisa Farmer Kerr, Dapo Ilo, Lotus Mallbris, Matthias Augustin. Am J Clin Dermatol 2017
25
66

A Phase IV, Randomized, Double-Blind, Placebo-Controlled Crossover Study of the Effects of Ustekinumab on Vascular Inflammation in Psoriasis (the VIP-U Trial).
Joel M Gelfand, Daniel B Shin, Abass Alavi, Drew A Torigian, Tom Werner, Maryte Papadopoulos, Junko Takeshita, Megan H Noe, Amit K Dey, Martin P Playford,[...]. J Invest Dermatol 2020
62
66

Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study.
Laura K Ferris, Elyssa Ott, Jingzhi Jiang, H Chih-Ho Hong, Shu Li, Chenglong Han, Wojciech Baran. J Dermatolog Treat 2020
21
66

Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study.
Kim Papp, Herve Bachelez, Antonio Costanzo, Peter Foley, Melinda Gooderham, Primal Kaur, Joanna Narbutt, Sandra Philipp, Lynda Spelman, Jolanta Weglowska,[...]. J Am Acad Dermatol 2017
75
66

Body Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of Adalimumab.
April W Armstrong, Delfina Guadalupe Villanueva Quintero, Cristina M Echeverría, Yihua Gu, Mahinda Karunaratne, Ofelia Reyes Servín. Am J Clin Dermatol 2016
19
66

Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3).
K A Papp, C L Leonardi, A Blauvelt, K Reich, N J Korman, M Ohtsuki, C Paul, S Ball, G S Cameron, J Erickson,[...]. Br J Dermatol 2018
63
66


Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Diamant Thaçi, Andrew Blauvelt, Kristian Reich, Tsen-Fang Tsai, Francisco Vanaclocha, Külli Kingo, Michael Ziv, Andreas Pinter, Sophie Hugot, Ruquan You,[...]. J Am Acad Dermatol 2015
369
66

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.
Alan Menter, Bruce E Strober, Daniel H Kaplan, Dario Kivelevitch, Elizabeth Farley Prater, Benjamin Stoff, April W Armstrong, Cody Connor, Kelly M Cordoro, Dawn M R Davis,[...]. J Am Acad Dermatol 2019
303
66


European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC.
A Nast, P Gisondi, A D Ormerod, P Saiag, C Smith, P I Spuls, P Arenberger, H Bachelez, J Barker, E Dauden,[...]. J Eur Acad Dermatol Venereol 2015
282
66



Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.
Mamitaro Ohtsuki, Akimichi Morita, Masatoshi Abe, Hidetoshi Takahashi, Noriko Seko, Alexander Karpov, Tomohiro Shima, Charis Papavassilis, Hidemi Nakagawa. J Dermatol 2014
67
66

Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy.
Kenneth B Gordon, Alice B Gottlieb, Craig L Leonardi, Boni E Elewski, Andrea Wang, Angelika Jahreis, Ralph Zitnik. J Dermatolog Treat 2006
90
66

Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis.
April W Armstrong, Luis Puig, Avani Joshi, Martha Skup, David Williams, Junlong Li, Keith A Betts, Matthias Augustin. JAMA Dermatol 2020
83
66



Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption.
K B Gordon, A B Gottlieb, R G Langely, P van de Kerkhof, K T Belasco, M Sundaram, M Okun, L Serra. J Eur Acad Dermatol Venereol 2015
16
66

Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study.
Carle Paul, Christopher E M Griffiths, Peter C M van de Kerkhof, Lluís Puig, Yves Dutronc, Carsten Henneges, Martin Dossenbach, Kristin Hollister, Kristian Reich. J Am Acad Dermatol 2019
59
66

Redefining the therapeutic objective in psoriatic patients candidates for biological therapy.
G Carretero, L Puig, J M Carrascosa, L Ferrándiz, R Ruiz-Villaverde, P de la Cueva, I Belinchon, E Vilarrasa, R Del Rio, J L Sánchez-Carazo,[...]. J Dermatolog Treat 2018
22
66

Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study.
R Bissonnette, T Luger, D Thaçi, D Toth, I Messina, R You, A Guana, T Fox, C Papavassilis, I Gilloteau,[...]. Br J Dermatol 2017
41
66

Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept.
Robert Bissonnette, Chantal Bolduc, Yves Poulin, Lyn Guenther, Charles W Lynde, Catherine Maari. J Am Acad Dermatol 2010
34
66

Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry.
Stefano Piaserico, Simone Cazzaniga, Sergio Chimenti, Alberto Giannetti, Mara Maccarone, Mauro Picardo, Andrea Peserico, Luigi Naldi. J Am Acad Dermatol 2014
42
66



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.